Cisapride (R 51619): A Nonselective 5-HT4 Agonist and hERG Channel Inhibitor for Cardiac Electrophysiology Research

Executive Summary: Cisapride (R 51619) is a nonselective 5-HT4 receptor agonist and a potent inhibitor of the hERG potassium channel, used primarily in cardiac electrophysiology and 5-HT4 signaling studies (APExBIO). It is solid at room temperature, highly soluble in DMSO (≥23.3 mg/mL), but insoluble in water, and demonstrates optimal stability when stored at -20°C. Cisapride enables predictive cardiotoxicity assessment in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and is a benchmark tool for arrhythmia risk evaluation (Grafton et al., 2021). Its use is supported by high-purity analytical documentation (HPLC, NMR, MSDS), and it is distributed by APExBIO for research applications. Limitations include its restricted clinical use and water insolubility, which may impact certain assay formats.

Biological Rationale

Cisapride (R 51619) is a small molecule that acts as a nonselective 5-HT4 receptor agonist and a potent hERG potassium channel inhibitor (APExBIO). The 5-HT4 receptor is implicated in gastrointestinal motility and cardiac signaling pathways. hERG channel inhibition is a key risk factor for drug-induced long QT syndrome and arrhythmias (Grafton et al., 2021). Cisapride's dual activity allows researchers to dissect 5-HT4-mediated effects while simultaneously evaluating hERG-related cardiotoxicity. The compound is widely used for in vitro studies of cardiac electrophysiology, arrhythmia mechanisms, and gastrointestinal motility. Its compatibility with iPSC-CMs enables high-throughput, translational research for early-stage drug safety assessment.

Mechanism of Action of Cisapride (R 51619)

Cisapride binds to and activates 5-HT4 receptors, stimulating adenylate cyclase and increasing intracellular cyclic AMP (cAMP) levels. This leads to enhanced acetylcholine release and increased gastrointestinal motility. Independently, Cisapride inhibits the hERG (KCNH2) potassium channel, a critical determinant of cardiac repolarization. hERG blockade prolongs the QT interval on the electrocardiogram and increases the risk of arrhythmogenic events (Grafton et al., 2021). The molecular structure of Cisapride—4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide—confers high affinity for both targets. Notably, these mechanisms are independent: 5-HT4 agonism is linked to gastrointestinal and cardiac signaling, while hERG inhibition directly affects cardiac electrophysiology (Related article, which focuses on mechanistic context; this article emphasizes recent screening advances).

Evidence & Benchmarks

• Cisapride at nanomolar concentrations (IC₅₀ ~6–30 nM) potently inhibits the hERG channel in human cell lines (Grafton et al., 2021).
• High-content phenotypic screening of iPSC-derived cardiomyocytes identifies Cisapride as a prototype hERG-mediated arrhythmogenic compound (Grafton et al., 2021).
• Cisapride is highly soluble in DMSO (≥23.3 mg/mL) and ethanol (≥3.47 mg/mL), but insoluble in water (per product documentation: APExBIO).
• Storage at -20°C preserves compound stability; long-term solution storage is not recommended (APExBIO).
• Quality control includes HPLC, NMR, and MSDS documentation, ensuring ≥99.70% purity (APExBIO).
• Cisapride demonstrates arrhythmogenic effects in both animal models and human iPSC-derived cells, enabling translational risk assessment (Related article; this article clarifies deep learning-based screening utility).

Applications, Limits & Misconceptions

Cisapride is applied in research settings to:

• Model drug-induced cardiac arrhythmias via hERG inhibition in vitro and in vivo.
• Probe 5-HT4 receptor signaling in gastrointestinal and cardiac tissues.
• Benchmark cardiotoxicity screening platforms using iPSC-derived cardiomyocytes and high-content imaging (Grafton et al., 2021).
• Serve as a reference compound in drug safety evaluation pipelines (Related article; this article updates with recent iPSC and AI-based screening data).

Common Pitfalls or Misconceptions

• Cisapride is not suitable for clinical use due to its arrhythmogenic risk profile.
• It does not selectively modulate only the 5-HT4 receptor; off-target effects at hERG and other channels are significant.
• Water insolubility may require careful assay design to avoid precipitation or artefacts.
• It is not a general prokinetic for all gastrointestinal transit models; activity is context-dependent.
• Long-term solution storage, even at low temperatures, may compromise compound integrity.

Workflow Integration & Parameters

Cisapride (R 51619) is distributed by APExBIO as a solid with ≥99.70% purity and is designated by SKU B1198 (product page). For experimental use, dissolve Cisapride in DMSO (≥23.3 mg/mL) or ethanol (≥3.47 mg/mL), and prepare fresh aliquots prior to each use; avoid water as a solvent. Store solid compound at -20°C. Use in concentrations consistent with assay requirements, typically in the nanomolar to low micromolar range for hERG channel assays. Employ iPSC-CMs or established cardiac models for arrhythmia screening, referencing high-content or phenotypic imaging protocols (Grafton et al., 2021). Analytical documentation (HPLC, NMR, MSDS) is supplied to verify compound identity and purity. For comparison with other tools and advanced mechanistic discussion, see this mechanistic synthesis, which this article extends with workflow and AI-screening relevance.

Conclusion & Outlook

Cisapride (R 51619) remains a critical tool for research into cardiac electrophysiology and drug-induced arrhythmia mechanisms. Its dual action as a nonselective 5-HT4 receptor agonist and potent hERG potassium channel inhibitor allows comprehensive modeling of both gastrointestinal and cardiac risks. Integration with iPSC-derived models and deep learning-based phenotypic screening has advanced its utility for predictive safety assessment (Grafton et al., 2021). Limitations include its lack of water solubility and unsuitability for clinical use, but its analytical robustness and workflow adaptability make it a gold-standard reference for translational research (APExBIO).